NASDAQ:ITOS iTeos Therapeutics (ITOS) Stock Price, News & Analysis $14.80 -0.70 (-4.52%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$14.74▼$16.2150-Day Range$14.02▼$17.9752-Week Range$8.20▼$18.75Volume1.05 million shsAverage Volume346,103 shsMarket Capitalization$534.62 millionP/E RatioN/ADividend YieldN/APrice Target$30.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get iTeos Therapeutics alerts: Email Address iTeos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside106.1% Upside$30.50 Price TargetShort InterestBearish8.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.21) to ($6.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsMedical Sector625th out of 910 stocksBiological Products, Except Diagnostic Industry100th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingiTeos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageiTeos Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about iTeos Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.93% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in iTeos Therapeutics has recently decreased by 0.79%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldiTeos Therapeutics does not currently pay a dividend.Dividend GrowthiTeos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ITOS. Previous Next 0.6 News and Social Media Coverage Search Interest7 people have searched for ITOS on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iTeos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about iTeos Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for iTeos Therapeutics are expected to decrease in the coming year, from ($4.21) to ($6.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iTeos Therapeutics is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iTeos Therapeutics is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiTeos Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about iTeos Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Mode MobilePre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.Claim Exclusive 100% Bonus: $0.25/Share About iTeos Therapeutics Stock (NASDAQ:ITOS)Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.Read More ITOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITOS Stock News HeadlinesAugust 28, 2024 | finanznachrichten.deiTeos Therapeutics Inc.: iTeos to Participate in Upcoming Investor ConferencesAugust 28, 2024 | globenewswire.comiTeos to Participate in Upcoming Investor ConferencesSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 25, 2024 | sg.finance.yahoo.comWe're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn RateAugust 20, 2024 | globenewswire.comiTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024August 19, 2024 | finance.yahoo.comITOS Sep 2024 13.000 put (ITOS240920P00013000)August 17, 2024 | finance.yahoo.comITOS Sep 2024 18.000 put (ITOS240920P00018000)August 14, 2024 | msn.comWells Fargo Initiates Coverage of iTeos Therapeutics (ITOS) with Overweight RecommendationSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 9, 2024 | finanznachrichten.deiTeos Therapeutics Inc.: iTeos Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for iTeos Therapeutics on Strong Financials and Promising Pipeline UpdatesAugust 8, 2024 | markets.businessinsider.comiTeos Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 7, 2024 | investing.comiTeos Therapeutics names new Chief Medical OfficerAugust 5, 2024 | globenewswire.comiTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical OfficerJuly 8, 2024 | seekingalpha.comiTeos Therapeutics: Rippling Waves Of TIGIT PessimismJuly 8, 2024 | globenewswire.comiTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSKJune 17, 2024 | globenewswire.comiTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung CancerMay 10, 2024 | marketwatch.comITeos Therapeutics Shares Surge 47% After Promising Tumor Treatment DataSee More Headlines Receive ITOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITOS CUSIPN/A CIK1808865 Webwww.iteostherapeutics.com Phone339-217-0161FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$30.50 High Stock Price Target$46.00 Low Stock Price Target$21.00 Potential Upside/Downside+106.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,640,000.00 Net MarginsN/A Pretax Margin-292.80% Return on Equity-18.18% Return on Assets-15.86% Debt Debt-to-Equity RatioN/A Current Ratio18.08 Quick Ratio18.08 Sales & Book Value Annual Sales$35 million Price / Sales15.27 Cash FlowN/A Price / Cash FlowN/A Book Value$18.18 per share Price / Book0.81Miscellaneous Outstanding Shares36,123,000Free Float31,608,000Market Cap$534.62 million OptionableOptionable Beta1.39 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Michel Detheux Ph.D. (Age 57)President, CEO & Director Comp: $1.04MMr. Matthew Gall (Age 47)Chief Financial Officer Comp: $648kMr. Matthew A. Call M.B.A. (Age 51)Chief Operating Officer Comp: $706.21kDr. Yvonne McGrath Ph.D. (Age 50)Chief Scientific Officer Ms. Adi OsovskyExecutive Vice President of LegalMr. Philippe BrantegemExecutive Vice President of Human ResourcesDr. Joyson Joseph Karakunnel FACP (Age 53)M.D., M.Sc., Interim Chief Medical Officer More ExecutivesKey CompetitorsTaysha Gene TherapiesNASDAQ:TSHANantKwestNASDAQ:NKVaxartNASDAQ:VXRTTwist BioscienceNASDAQ:TWSTVericelNASDAQ:VCELView All CompetitorsInsiders & InstitutionsClearline Capital LPBought 156,894 shares on 8/16/2024Ownership: 0.434%Algert Global LLCBought 6,139 shares on 8/16/2024Ownership: 0.369%Millennium Management LLCSold 641,676 shares on 8/15/2024Ownership: 0.668%AQR Capital Management LLCSold 56,870 shares on 8/15/2024Ownership: 0.081%The Manufacturers Life Insurance Company Bought 690 shares on 8/15/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions ITOS Stock Analysis - Frequently Asked Questions How have ITOS shares performed this year? iTeos Therapeutics' stock was trading at $10.95 at the start of the year. Since then, ITOS stock has increased by 35.2% and is now trading at $14.80. View the best growth stocks for 2024 here. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its quarterly earnings data on Thursday, August, 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.86. The business earned $35 million during the quarter, compared to analyst estimates of $4.20 million. When did iTeos Therapeutics IPO? iTeos Therapeutics (ITOS) raised $151 million in an initial public offering on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are iTeos Therapeutics' major shareholders? iTeos Therapeutics' top institutional shareholders include Dimensional Fund Advisors LP (2.51%), Renaissance Technologies LLC (1.55%), Candriam S.C.A. (1.41%) and Millennium Management LLC (0.67%). Insiders that own company stock include Boxer Capital, Llc, Michel Detheux, Matthew Gall, Bioventures 2018 LP Mpm, Bioventures 2014 LP Mpm, Detlev Biniszkiewicz, David Hallal, Joanne Jenkins Lager, Ansbert Gadicke and Yvonne Mcgrath. View institutional ownership trends. How do I buy shares of iTeos Therapeutics? Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of iTeos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG) and Centene (CNC). This page (NASDAQ:ITOS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITOS Stock Alerts